Envista: 2025 Full-Year Revenue Reaches $2.72 Billion, Spark Business Turns Profitable in H2

*Source: Envista Reports Fourth Quarter 2025 Results

Revenue and Profit Both Increase / Q4 Core Sales Grow 10.8% / Spark Business Turns Profitable in H2

DentalGoodNews | Recently, Envista Holdings Corporation released its Q4 and full-year 2025 financial results. The company specializes in dental products, with business covering implant systems, orthodontics, digital imaging, and dental consumables, owning core brands such as Nobel Biocare, Ormco, DEXIS, and Kerr. In Q4, Envista achieved revenue of $751 million (approximately RMB 5.21 billion), with core sales growing 10.8% year-over-year. For the full year, revenue reached $2.72 billion (approximately RMB 18.87 billion), with core sales growing 6.5% year-over-year.

*Source: Envista Reports Fourth Quarter 2025 Results

In terms of profitability, Q4 GAAP net income was $33 million (approximately RMB 229 million), a significant improvement compared to the same period last year; adjusted net income was $63 million (approximately RMB 437 million); adjusted EBITDA was $111 million (approximately RMB 770 million), up 22% year-over-year, with EBITDA margin at 14.8%, up 90 basis points from the prior year; adjusted earnings per share (EPS) of $0.38 (approximately RMB 2.64), up 58% year-over-year.

For the full year 2025, Envista's GAAP net income was $47 million (approximately RMB 326 million), a marked improvement from the loss position in the prior year; adjusted net income was $202 million (approximately RMB 1.401 billion), up approximately 59.1% year-over-year. Adjusted EBITDA was $372 million (approximately RMB 2.581 billion), up 26% year-over-year, with margin improving to 13.7%, up 190 basis points from the prior year; adjusted EPS of $1.19 (approximately RMB 8.26), up 63% year-over-year.

Regarding regional markets, the company noted in its conference call that China currently accounts for approximately 7% of Envista's global revenue. Impacted by orthodontic Volume-Based Procurement (VBP) expectations, China business experienced high double-digit decline in Q4 2024, primarily due to proactive channel destocking ahead of VBP; whereas in Q4 2025, last year's low base provided support for quarterly performance (management stated that factors including China and the diagnostic business's low base from last year contributed approximately 3 percentage points to Q4 growth). Management indicated that China market may still show certain quarterly volatility, but overall performance is in line with company expectations.

Additionally, the company expects China to advance the first round of VBP in orthodontics and the second round of VBP for implants in 2026, though specific timing remains uncertain. Management noted in the conference call that past experience shows VBP implementation is typically preceded by 1-2 quarters of order contraction, while post-execution, channel restocking may bring phased recovery. In the implant segment, the second round of VBP price reduction may be lower than the first round, approximately in the 10%-20% range; in orthodontics, price reductions are expected to be accompanied by volume increases, but due to the longer treatment cycle of orthodontics (approximately 18 months), volume growth may be lower than in the implant segment.

The company emphasized that related impacts have been incorporated into the company's overall 2026 operating assumptions, but quarterly-level volatility may still create disruptions to China business revenue and margin. Management stated they will continue to offset through pricing, supply chain adjustments, and operational efficiency.

*Source: Envista Reports Fourth Quarter 2025 Results

← 滑动浏览更多图片 Swipe for more →

In terms of business structure, Specialty Products & Technologies achieved Q4 revenue of $476 million (approximately RMB 3.303 billion), with core growth of 10.9%. Spark clear aligners maintained high-speed growth after adjusting for deferred revenue factors, brackets and archwire business achieved double-digit growth, implant business recorded mid-single-digit growth in both premium and challenger product lines, and the segment's adjusted operating margin improved to 16.2%. For the full year, the Specialty Products & Technologies segment achieved revenue of $1.753 billion (approximately RMB 12.162 billion) in 2025, compared to $1.616 billion (approximately RMB 11.212 billion) in 2024; core sales grew 6.3%. Its full-year GAAP operating profit was $191 million (approximately RMB 1.325 billion), a substantial improvement from the prior year; adjusted operating profit was $260 million (approximately RMB 1.804 billion), with adjusted operating margin rising from 10.8% in 2024 to 14.9%.

Equipment & Consumables achieved Q4 revenue of $275 million (approximately RMB 1.908 billion), with core growth of 10.7%. The consumables business achieved high single-digit to double-digit growth, imaging and diagnostic equipment maintained double-digit growth globally, with particularly strong performance in North America, though segment margin was slightly pressured by transactional foreign exchange impacts. For the full year, the Equipment & Consumables segment achieved revenue of $967 million (approximately RMB 6.709 billion) in 2025, compared to $894 million (approximately RMB 6.203 billion) in 2024; core sales grew 6.9%, slightly higher than the Specialty Products segment. Its full-year GAAP operating profit was $158 million (approximately RMB 1.096 billion), adjusted operating profit was $184 million (approximately RMB 1.277 billion), but adjusted operating margin was 19.0%, a slight decline from 20.8% in 2024.

*Source: Envista Reports Fourth Quarter 2025 Results

In terms of cash flow, Q4 operating cash flow was $108 million (approximately RMB 749 million), free cash flow was $92 million (approximately RMB 638 million), with free cash flow conversion rate of 145%. Full-year operating cash flow was $276 million (approximately RMB 1.915 billion), free cash flow was $231 million (approximately RMB 1.603 billion), with conversion rate of 114%.

Regarding capital allocation, the company repurchased 9.2 million shares for approximately $166 million in total during 2025 (approximately RMB 1.152 billion); including 1.2 million shares repurchased in Q4, with approximately $84 million (approximately RMB 583 million) in repurchase authorization remaining at period end.

*Source: Envista Reports Fourth Quarter 2025 Results

For 2026, the company expects full-year 2026 core sales growth of 2%-4%, adjusted EBITDA growth of 7%-13%, adjusted EPS of $1.35-$1.45 (approximately RMB 9.37-10.06), and free cash flow conversion rate of approximately 100%, with overall guidance consistent with its medium-term value creation targets.